View Older Stories
-
Cytokinetics (CYTK) Misses Q1 EPS by 2c
-
Cytokinetics (CYTK) PT Raised to $83 at BofA Securities
-
BofA: Bristol update may boost Cytokinetics shares
-
Cytokinetics announces nine presentations at heart failure conference
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
Wells Fargo Starts Cytokinetics (CYTK) at Overweight
-
Evercore ISI on Cytokinetics (CYTK): 'positive edge' into topline Ph3 data
-
Cytokinetics (CYTK) PT Raised to $100 at Mizuho
-
Cytokinetics (CYTK) PT Raised to $75 at JPMorgan on Favorable Near-Term Outlook
-
Stifel on Cytokinetics (CYTK): 'We Think The Trial Likely Works, Positioning Afi As The Best/Only Drug Available For The Entire HCM Spectrum'
-
Leerink Partners Reiterates Outperform Rating on Cytokinetics (CYTK) following conference
-
Cytokinetics (CYTK) PT Raised to $69 at UBS Amid Improved nHCM Outlook
-
Cytokinetics (CYTK) PT Raised to $67 at BofA Securities
-
Cytokinetics (CYTK) PT Raised to $85 at Needham
-
Cytokinetics (CYTK) Reiterated at Overweight by Cantor Fitzgerald: Encouraging Signs
-
Cytokinetics (CYTK) PT Raised to $96 at Citizens: Still Top Pick Ahead of ACACIA-HCM
-
Cytokinetics (CYTK) Tops Q4 EPS by 6c
-
Cytokinetics gets European approval for heart drug MYQORZO
-
B.Riley Reiterates Buy Rating on Cytokinetics (CYTK)
-
Barclays Assumes Cytokinetics (CYTK) at Overweight
-
Truist: 'We remain buyers of CYTK following KOL feedback'
-
Cytokinetics launches MYQORZO for hypertrophic cardiomyopathy in US
-
Cytokinetics (CYTK) PT Raised to $90 at Jefferies
-
Cytokinetics (CYTK) PT Raised to $84 at Truist Securities
-
Cytokinetics (CYTK) PT Raised to $84 at Needham
-
Cytokinetics (CYTK) PT Raised to $136 at H.C. Wainwright
-
Cytokinetics (CYTK) PT Raised to $95 at RBC Capital
-
Cytokinetics (CYTK) PT Raised to $88 at Citizens
-
Here's the list of top biotech stocks to own for 2026
-
Cytokinetics (CYTK) halted, news pending
-
Goldman Sachs Upgrades Cytokinetics (CYTK) to Buy
-
Cytokinetics receives China approval for heart drug MYQORZO
-
Cytokinetics receives positive CHMP opinion for heart drug MYQORZO
-
Piper Sandler on Biotechnology: 'What Commercial Names to Own in 2026?'
-
Cytokinetics (CYTK) PT Raised to $61 at UBS
-
Cytokinetics (CYTK) PT Raised at RBC Capital into Aficamten 2026 Launch
-
Cytokinetics presents additional MAPLE-HCM trial data at medical conferences
-
Cytokinetics (CYTK) Misses Q3 EPS by 98c
-
Cantor Fitzgerald Reiterates Cytokinetics (CYTK) at Overweight Post Model Update
-
Cytokinetics (CYTK) PT Raised to $82 at Barclays
-
Cytokinetics (CYTK) PT Lowered to $95 at Stifel
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
Cytokinetics (CYTK) October 40 calls and January 55 calls active
-
Stifel Reiterates Buy Rating on Cytokinetics (CYTK)
-
Citizens JMP Reiterates Market Outperform Rating on Rapport Therapeutics (RAPP)
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
H.C. Wainwright Reiterates $120 PT Cytokinetics (CYTK), Top Pick
-
Cytokinetics meets with FDA on aficamten drug application
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
Jefferies on Cytokinetics (CYTK): 'we await some indication that these initiatives will deliver the intended results'

